I'm expanding my portfolio with undervalued REITs like Healthpeak Properties, aiming to capitalize on market overreactions and irrational selling. Healthpeak's valuation is disconnected from its fundamentals; current market pessimism doesn't reflect the cyclical nature of real estate supply and demand. Healthpeak's disciplined capital allocation, including selective buybacks and reinvestment, reflects prudent management in a volatile rate environment.
Healthpeak Properties trades at a deep discount, with limited downside risk and a well-covered 6.9% dividend yield. The balance sheet is strong, with net debt/EBITDAre at 5.2x and $2.3 billion in liquidity. Valuation is driven by lab space concerns, despite lab space being only 40% of its portfolio, whereas its medical office and senior housing segments remain stable.
Healthpeak Properties, Inc. (NYSE:DOC ) Q2 2025 Earnings Conference Call July 25, 2025 10:00 AM ET Company Participants Andrew Johns - Senior Vice President of Investor Relations Kelvin O. Moses - Chief Financial Officer Mark Theine - Corporate Participant Scott M.
DOC's second-quarter results reflect the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.
While the top- and bottom-line numbers for Healthpeak (DOC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.46 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.45 per share a year ago.
DOC's Q2 earnings are likely to benefit from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Get a deeper insight into the potential performance of Healthpeak (DOC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Healthpeak Properties is strategically focused on Class A outpatient and life science real estate, benefiting from demographic tailwinds and supply constraints in key markets. The recent Physicians Realty Trust merger enhances scale, operational synergies, and defensibility, positioning Healthpeak for steady FFO growth as sector fundamentals improve. Despite high leverage and capital allocation risks, Healthpeak trades at a significant discount to historical valuation multiples, offering attractive long-term total return potential.
Healthpeak Properties offers strong upside potential, driven by robust AFFO growth, merger synergies, and a well-covered 7% dividend yield. Recent earnings show double-digit revenue and AFFO growth, with management guiding for continued double-digit AFFO growth and solid same-store NOI in 2025. Share repurchases, a switch to monthly dividends, and a healthy balance sheet further support long-term price appreciation and income stability.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Healthpeak offers a nearly 7% yield, strong dividend coverage, and trades at a deep discount to private market value, making it a compelling buy. The merger with Physicians Realty Trust created a diversified, cost-efficient REIT with reliable income from medical offices and upside from labs and senior housing. Risks like soft lab demand and higher rates are cushioned by long leases, fixed debt, and strong outpatient/CCRC performance, ensuring dividend security.